Wed May 18, 2011 6:13pm EDT
(For full coverage of new data on cancer studies to be
presented at the American Society of Clinical Oncology, see:
)
* Progression-free survival of 3.4 mos vs 2.7 mos* Side effects: hand/foot reaction, low white blood cellsLOS ANGELES, May 18 (Reuters) - Nexavar, the cancer drug
sold by Onyx Pharmaceuticals Inc (ONXX.O) and Bayer AG
(BAYGn.DE), was shown to delay tumor progression in women with
advanced breast cancer, according
No comments:
Post a Comment